Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

AACR 2009: Genetic variants in microRNA processing pathway genes and ovarian cancer risk

AACR 2009

18 - 22 Apr 2009

Published: 30 Apr 2009

Views: 16526

Rating:

Save

Professor Xifeng Wu - Department of Epidemiology, University of Texas M.D. Anderson Cancer Center, USA

Xifeng Wu, M.D., Ph.D., professor, department of epidemiology, University of Texas M.D. Anderson Cancer Center, presenting at AACR 2009, Denver: Genetic Variants in MicroRNA Processing Pathway Genes and Ovarian Cancer Risk

Related Videos

Atezolizumab versus placebo in combination with bevacizumab and non-platinum...

Prof Frederik Marmé - Heidelberg University, Heidelberg, Germany

Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer ( Prof Frederik Marmé - Heidelberg University, Heidelberg, Germany )

Some advanced epithelial ovarian cancer patients can avoid a lymphadenectomy...

Prof Jean-Marc Classe - Nantes Université, Nantes, France

Some advanced epithelial ovarian cancer patients can avoid a lymphadenectomy without impacting survival outcomes ( Prof Jean-Marc Classe - Nantes Université, Nantes, France )

Immunotherapy promise for gynaecologic extra-renal clear cell carcinomas

Prof Don Dizon - Lifespan Cancer Institute, Providence, USA

Immunotherapy promise for gynaecologic extra-renal clear cell carcinomas ( Prof Don Dizon - Lifespan Cancer Institute, Providence, USA )

Monitoring ovarian function in oncology studies

Dr Elizabeth Trice Loggers - University of Washington, Seattle, USA

Monitoring ovarian function in oncology studies ( Dr Elizabeth Trice Loggers - University of Washington, Seattle, USA )

Novel therapies and combinations in ovarian cancer

Dr Alexandria Leary - Institute Gustave Roussy, Villejuif, France

Novel therapies and combinations in ovarian cancer ( Dr Alexandria Leary - Institute Gustave Roussy, Villejuif, France )

Synthetic biology and precision medicine in blood and gynaecological cancers

Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria...

Synthetic biology and precision medicine in blood and gynaecological cancers ( Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria, South Africa )

First-line chemotherapy with atezolizumab and bevacizumab significantly...

Dr Ana Oaknin - Vall d´Hebron Institute of Oncology, Barcelona, Spain

First-line chemotherapy with atezolizumab and bevacizumab significantly improves survival for R/M cervical cancer ( Dr Ana Oaknin - Vall d´Hebron Institute of Oncology, Barcelona, Spain )

Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for...

Prof Ignace Vergote - UZ Leuven, Leuven, Belgium

Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer ( Prof Ignace Vergote - UZ Leuven, Leuven, Belgium )

Atezolizumab with platinum-based CT and niraparib show no improvement in...

Dr Antonio Gonzalez Martin - Cancer Center Clínica Universidad de Navarra...

Atezolizumab with platinum-based CT and niraparib show no improvement in survival for rOC ( Dr Antonio Gonzalez Martin - Cancer Center Clínica Universidad de Navarra, Madrid, Spain )

More from ecancer